Page 334 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

308 Elana J. Bernstein and Robert F. Spiera

[28] Watts RA, Carruthers DM, Scott DG. Isolated nail fold vasculitis in rheumatoid
arthritis. Ann. Rheum. Dis., 1995; 54:927-929.

[29] Agarwal V, Singh R, Wiclaf, et al. A clinical, electrophysiological, and pathological
study of neuropathy in rheumatoid arthritis. Clin. Rheumatol., 2008; 27:841-844.

[30] Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients
developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic
immunosuppression. Ophthalmology, 1984; 91: 1253-1263.

[31] Messmer EM, Foster CS. Destructive corneal and scleral disease associated with
rheumatoid arthritis. Medical and surgical management. Cornea, 1995; 14:408-417.

[32] Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in
rheumatoid arthritis. Scand. J. Rheumatol., 2004; 33:65-72.

[33] Harper L, Cockwell P, Howie AJ, et al. Focal segmental necrotizing glomerulonephritis
in rheumatoid arthritis. QJM, 1997; 90:125-132.

[34] Pagnoux C, Mahr A, Cohen P, et al. Presentation and outcome of gastrointestinal
involvement in systemic necrotizing vasculitides: analysis of 62 patients with
polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss
syndrome, or rheumatoid arthritis-associated vasculitis. Medicine, 2005; 84:115-128.

[35] Puéchal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis
in rheumatoid arthritis. Arthritis Rheum., 1995; 38:1618-1629.

[36] Puechal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in
patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann.
Rheum. Dis., 2008; 67:880-884.

[37] Ball J. Rheumatoid arthritis and polyarteritis nodosa. Ann. Rheum. Dis., 1954; 13:277-
290

[38] Ropes MW, Bennet GA, Cobb S, et al. 1958 revision of diagnostic criteria for
rheumatoid arthritis. Bull. Rheum. Dis., 1958; 9:175-176.

[39] Voskuyl AE, Zwinderman AH, Westedt ML, et al. The mortality of rheumatoid
vasculitis compared with rheumatoid arthritis. Arthritis Rheum., 1996; 39:266-271.

[40] Turesson C, Matteson EL. Management of extra-articular disease manifestations in
rheumatoid arthritis. Curr. Opin. Rheumatol., 2004; 16:206-211.

[41] Abel T, Andrews BS, Cunningham PH, et al. Rheumatoid vasculitis: effect of
cyclophosphamide on the clinical course and levels of circulating immune complexes.
Ann. Intern. Med., 1980; 93:407-413.

[42] Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis
by infliximab. Ann. Rheum. Dis., 2003; 62:587-588.

[43] Hellmann M, Jung N, Owczarczyk K, et al. Successful treatment of rheumatoid
vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid
arthritis. Rheumatology (Oxford), 2008; 47:929-930.

[44] Maher LV, Wilson JG. Successful treatment of rheumatoid vasculitis-associated foot
drop with rituximab. Rheumatology (Oxford), 2006; 45:1450-1451.

[45] Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody
infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.
Rheumatology (Oxford), 2002; 41:1126-1132.

[46] Garcia-Porrua C, Gonzalez-Gay MA. Successful treatment of refractory mononeuritis
multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha
monoclonal antibody infliximab. Rheumatology (Oxford), 2002; 41:234-235.

Complimentary Contributor Copy